Narrative
When anti-TNF therapies (which block tumour necrosis factor) were first licensed in 1999 only a few hundred patients with rheumatoid arthritis had received them, most for relatively short periods of time. Although the drugs represented a major breakthrough, ‘real-world’ effectiveness and safety were unproven. Research at the University of Manchester (UoM) has addressed this knowledge gap and has successfully refined the ways in which anti-TNF drugs are used around the world, leading directly to more effective prescribing and improved patient outcomes. The research has also provided strong evidence that women do not need to discontinue anti-TNF treatment prior to conception.| Impact date | 2014 |
|---|---|
| Category of impact | Health impacts, Societal impacts, Economic impacts |
| Impact level | Benefit |
Related content
-
Research output
-
Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a Large UK National Cohort Study
Research output: Contribution to journal › Article › peer-review
-
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
Research output: Contribution to journal › Article › peer-review
-
Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
Research output: Contribution to journal › Article › peer-review
-
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
Research output: Contribution to journal › Article › peer-review
-
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)
Research output: Contribution to journal › Article › peer-review